middle.news
How Artrya’s $80M Raise and FDA Nod Propel Its US Coronary AI Ambitions
9:06pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How Artrya’s $80M Raise and FDA Nod Propel Its US Coronary AI Ambitions
9:06pm on Wednesday 25th of February, 2026 AEDT
Key Points
44.4% increase in half-year loss to $10.7 million
FDA clearance obtained for Salix Coronary Plaque module
Three US foundation customers contracted with long-term agreements
Successful $80 million capital raise to fund US commercialisation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ARTRYA (ASX:AYA)
OPEN ARTICLE